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The oral antidiabetic drug metformin is known to exhibit anti-inflammatory properties
through activation of AMP kinase, thus protecting various brain tissues as cortical
neurons, for example. However, the effect of metformin on the substantia nigra
(SN), the main structure affected in Parkinson’s disease (PD), has not yet been
studied in depth. Inflammation is a key feature of PD and it may play a central
role in the neurodegeneration that takes place in this disorder. The aim of this work
was to determine the effect of metformin on the microglial activation of the SN of
rats using the animal model of PD based on the injection of the pro-inflammogen
lipopolysaccharide (LPS). In vivo and in vitro experiments were conducted to study the
activation of microglia at both the cellular and molecular levels. Our results indicate that
metformin overall inhibits microglia activation measured by OX-6 (MHCII marker), IKKβ
(pro-inflammatory marker) and arginase (anti-inflammatory marker) immunoreactivity. In
addition, qPCR experiments reveal that metformin treatment minimizes the expression
levels of several pro- and anti-inflammatory cytokines. Mechanistically, the drug
decreases the phosphorylated forms of mitogen-activated protein kinases (MAPKs) as
well as ROS generation through the inhibition of the NADPH oxidase enzyme. However,
metformin treatment fails to protect the dopaminergic neurons of SN in response to
intranigral LPS. These findings suggest that metformin could have both beneficial and
harmful pharmacological effects and raise the question about the potential use of
metformin for the prevention and treatment of PD.
Keywords: neuroinflammation, Parkinson’s disease, metformin, microglia activation, animal model, AMPK
Abbreviations: CX3CR1, CX3C chemokine receptor 1; ELISA, enzyme-linked immunosorbent assay; GFAP, glial fibrillary
acidic protein; IKKβ, IκB kinase β; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide;
MAPK, mitogen-activated protein kinase; MCP-1, Monocyte chemoattractant protein 1; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; NLRP3, nucleotide-binding oligomerization domain-like receptor protein containing a pyrin domain
3; PBS, phosphate-buffered saline; PD, Parkinson’s disease; ROS, reactive oxygen species; SN, substantia nigra; TBS,
Tris-buffered saline; TBST, TBS Tween; TH, tyrosine hydroxylase; TNF, tumor necrosis factor.
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 November 2018 | Volume 12 | Article 440
fncel-12-00440 November 19, 2018 Time: 14:41 # 2
Tayara et al. Metformin Beneficial and Harmful Effects
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
featuring the loss of the dopaminergic neurons in the SN and
Lewy pathology (intracellular accumulation of α-synuclein and
other proteins in the so-called Lewy bodies), with a resultant
alteration of the motor function that produces the loss of
autonomy; cognitive function and mood are also impaired
(Marinus et al., 2018; Odin et al., 2018; Sojitra et al., 2018).
The disease occurs in two forms with different causes and
prevalence, so that the so-called early onset family form is due
to mutations in a few genes and represent no more than 10% of
cases, while the most frequent form, associated with aging (the
idiopathic or sporadic form, typically occurring around 65 years
of age), shows a diffuse etiology. Several factors affecting common
processes in cells, such as the loss of mitochondrial function
(and the associated oxidative stress) induced or not by toxins,
the alteration of proteostatic processes (including autophagy and
the ubiquitin-proteasome pathway) or the neuroinflammatory
processes associated or not with infections, have been found
to contribute to the onset and development of sporadic cases
(Herrera et al., 2015; De Miranda et al., 2018; Huang H.K. et al.,
2018; Scudamore and Ciossek, 2018; Zeng et al., 2018).
The early report by McGeer et al. (1988) showing the presence
of microglia in parkinsonian brains has been followed by others
that confirm the existence of a neuroinflammatory process
underlying many cases of the disease (Klegeris et al., 2007;
McGeer and McGeer, 2008). In addition, activated microglia
show increased production of pro-inflammatory cytokines
(Tansey et al., 2007; Hirsch and Hunot, 2009). One point in favor
of the role of neuroinflammation in PD is the lower incidence
(around 50%) of the disease in chronic users of non-steroidal
anti-inflammatory drugs and cyclooxygenase inhibitors (Chen
et al., 2003, 2005; Esposito et al., 2007). From this observation,
many studies have attempted to prove the capacity of different
substances with anti-inflammatory properties to reduce the
progression of PD (Cayero-Otero et al., 2018). These substances
include non-steroidal anti-inflammatory drugs, classical steroid
anti-inflammatory agents, natural substances and drugs used
for quite different goals. However, more compelling evidence
supporting the involvement of neuroinflammation in PD
pathogenesis relies on genome-wide association studies, which
have found a genetic association with PD susceptibility in the
human leukocyte antigen region (Nalls et al., 2014) and other
polymorphisms related to the immune system including TNF,
TNFR1, IL-1β, triggering receptor expressed on myeloid cells 2,
IL-1 receptor antagonist and CD14 (Hirsch and Hunot, 2009;
Rayaprolu et al., 2013). These studies highlight the importance
of neuroinflammation-based animal models of PD, including
those induced by injecting pro-inflammatory compounds such
as thrombin (Carreño-Müller et al., 2003), tissue plasminogen
activator (Villarán et al., 2009) or LPS within the SN (Castaño
et al., 1998). Here, we took advantage of the intranigral injection
of LPS in rats. LPS is the active endotoxin of Gram-negative
bacteria that initiates the immune response after bacterial
infection (Kielian and Blecha, 1995; Holst et al., 1996). LPS
is a Toll-like receptor 4 ligand, present in microglial cells but
not in neurons, that plays a critical role in the activation and
proliferation of microglia (Beutler et al., 2001). It has been shown
that subtoxic doses of LPS exacerbate disease progression in an
animal model of PD (Godoy et al., 2008), thus supporting the
hypothesis that brain inflammation may play a significant role in
PD progression.
Metformin (metformin hydrochloride) is an extended used
oral antidiabetic drug that reduces hepatic glucose production
and decreases insulin resistance and the levels of plasma insulin
in fasting. These actions seem to be mainly mediated by the
activation of the AMP kinase (AMPK). Interestingly, several
authors have shown that metformin also has anti-inflammatory
properties, both peripherally (Mamputu et al., 2003; Li et al.,
2005; Isoda et al., 2006) and centrally (Liu et al., 2014; Zhu et al.,
2015; Ismaiel et al., 2016). So far, only a few studies have evaluated
the effects of metformin in animal models of neurodegenerative
disease. With these precedents, we wondered if metformin could
be a suitable adjuvant for the treatment of PD. Therefore, the aim
of this study was to determine the effect of metformin on the
glial and neuronal cells of the SN of rats using the LPS animal
model mentioned above. In vitro cell culture of BV2 cells was
also used to study the activation of microglia. Our results show
that metformin reduces microglial activation, at both cellular and
molecular levels, but fails to protect dopaminergic neurons from
the damage induced by LPS.
MATERIALS AND METHODS
Cell Culture
For all cell culture experiments, we used murine microglial BV2
cell line. These cells were cultured in DMEM (Invitrogen,
Carlsbad, CA, United States) supplemented with 10%
heat-inactivated fetal bovine serum (Sigma-Aldrich, St. Louis,
MO, United States), streptomycin (100 mg/ml), and penicillin
(100 IU/ml), under 100% humidity and 5% CO2. Experiments
were performed in reduced 5% heat-inactivated fetal bovine
serum media.
For testing the effect of metformin on the pro- and
anti-inflammatory phenotypes of microglial cells, BV2 cells
were treated with LPS (pro-inflammatory phenotype inducer,
1 µg/ml, Sigma-Aldrich, St. Louis, MO, United States) or IL-4
(anti-inflammatory phenotype inducer, 20 ng/ml, Sigma-Aldrich,
St. Louis, MO, United States), with and without metformin
(1 mM, Dianben R© 1000 mg, MERK) for 12 h. The effect
on production of ROS was measured by treating cells with
LPS and/or metformin for 24 h. The effect on inflammasome
activation was tested by Western blot and ELISA, treating cells
with LPS and/or metformin for 3 h and then with ATP (1 mM,
Sigma-Aldrich, St. Louis, MO, United States) as the second signal
for inflammasome activation (Martinon et al., 2002).
Animals and Surgery
Male albino Wistar rats (200–270 g) were used for these studies.
The rats were kept at constant room temperature of 22 ± 1◦C
and relative humidity (60%) with a 12-h light–dark cycle with free
access to food and water. Rats were anesthetized with isoflurane
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and positioned in a stereotaxic apparatus (Kopf Instruments,
Tujunga, CA, United States) to conform to the brain atlas of
Paxinos and Watson (1986). Injections into the SN were made
5.5 mm posterior, 1.8 mm lateral and 8.3 mm ventral to the
bregma at day 1.
Experiments were carried out in accordance with the
Guidelines of the European Union Directive (2010/63/EU) and
Spanish regulations (BOE 34/11370-421, 2013) for the use of
laboratory animals; the study was approved by the Scientific
Committee of the University of Seville.
Animals were divided into four groups according to two
different variables (Figure 1): solution administered orally by a
plastic enteral feeding tube (tap water or 150 mg/kg of metformin
dissolved in tap water, 4 mL/kg) and product injected in the SN
(2 µL of saline solution or 2 µg of LPS dissolved in 2 µL of
saline solution). In group I (the control group), animals received
a single intranigral injection of saline solution (Monastral Blue
inert tracer, 1% in saline solution; Sigma-Aldrich, St. Louis,
MO, United States) the 1st day. Twice a day, animals received
4 mL/kg of tap water through the plastic tube for 7 days. Group
II received a single intranigral injection of saline solution and
two daily doses of metformin dissolved in tap water for 7 days.
Group III received a single intranigral injection of LPS (from
Escherichia coli, serotype 026:B6; Sigma-Aldrich, St. Louis, MO,
FIGURE 1 | Experimental design: groups and treatments in vivo. Tap water or
metformin were administered orally, twice a day for 7 days to the
corresponding groups. Saline solution or LPS were injected intranigrally to the
corresponding groups the 1st day of the experiment, before tap water or
metformin were administered.
United States) the 1st day and 4 mL/kg of tap water through the
plastic tube twice a day for 7 days. Group IV received a single
intranigral injection of LPS the 1st day and two daily doses of
metformin dissolved in tap water for 7 days. The first dose of
metformin or water was administrated 1 h before intranigral
injection. All animals were sacrificed by perfusion or decapitation
7 days after the initiation of treatment, unless otherwise stated.
Immunohistological Evaluation: Tyrosine
Hydroxylase (TH), Glial Fibrillary Acidic
Protein (GFAP) and OX-6
Animals used for immunohistochemistry completed 7 days of
treatment with water/metformin. One week after the surgical
procedure in the SN, animals were perfused through the heart
under deep anesthesia (isoflurane) with 150–200 mL of 4%
paraformaldehyde in phosphate buffer, pH 7.4. The brains were
removed and then cryoprotected serially in sucrose dissolved
in PBS, pH 7.4, first (24 h) in 10% sucrose, next (24 h)
in 20% sucrose, and finally in 30% sucrose until they sank
(2–5 days). Brains were then frozen in isopentane at −20◦C, and
sections of 20 µm thickness were cut on a cryostat at −20◦C,
and mounted in gelatine-coated slides. Primary antibodies used
were rabbit-derived anti-TH (Sigma-Aldrich, St. Louis, MO,
United States, 1:300), mouse-derived anti-GFAP (Chemicon
International Inc.; 1: 300) and mouse-derived OX-6 (Serotec,
Oxford, United Kingdom; 1: 200).
Sections were washed and then treated with 0.3% hydrogen
peroxide in methanol for 15 min, washed again, and incubated in
a solution containing TBS and 1% horse (for GFAP and OX-6)
or goat (for TH) serum for 60 min in a humid chamber. Slides
were drained and further incubated with the primary antibody in
TBS containing 1% horse/goat serum and 0.25% Triton-X-100 for
24 h. Sections were then incubated for 2 h with biotinylated horse
anti-mouse (for GFAP and OX-6) or biotinylated goat anti-rabbit
(for TH) IgG (Vector, 1:200). The secondary antibody was diluted
in TBS containing 0.25% Triton-X-100, and its addition was
preceded by three 10-min rinses in TBS. Sections were then
incubated with ExtrAvidin R©-Peroxidase solution (Sigma-Aldrich,
St. Louis, MO, United States, 1:100), for 1 h. The peroxidase was
visualized with a standard diaminobenzidine/hydrogen reaction
for 5 min.
Immunohistochemistry Data Analysis
Analysis were made in a bounded region of the SN with a length
of 300 microns in the anterior–posterior axis centered at the point
of injection (5.5 mm with respect to bregma), that is, between
5.35 and 5.65 mm with respect to bregma. In each case, five
sections per animal were used, with random starting point and
systematically distributed through the anterior–posterior axis of
the analyzed region. For the measurement of areas lacking GFAP
immunoreactivity, the AnalySIS imaging software (Soft Imaging
System GmbH, Münster, Germany) coupled to a Polaroid DMC
camera (Polaroid, Cambridge, MA, United States) attached to a
Leica light microscope (Leica Mikroskopie, Wetzlar, Germany)
was used. For counting cells showing OX-6 immunoreactivity, a
systematic sampling of the area occupied by the OX-6-positive
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cells in each section was made from a random starting point
with a grid adjusted to count five fields per section. An unbiased
counting frame of known area (40 µm × 25 µm = 1000 µm2)
was superimposed on the tissue section image under a 100× oil
immersion objective. The different types of OX-6-positive cells
(displaying different shapes depending on their activation state)
were counted as a whole and expressed as cells per mm2. The
number of TH-positive neurons in the SN was estimated using
a fractionator sampling design (Gundersen et al., 1988). Counts
were made at regular predetermined intervals (x = 150 µm and
y = 200 µm) within each section. An unbiased counting frame
of known area (40 µm× 25 µm = 1000 µm2) was superimposed
on the tissue section image under a 100× oil immersion objective.
Therefore, the area sampling fraction is 1000/(150× 200) = 0.033.
The entire z-dimension of each section was sampled; hence, the
section thickness sampling fraction was 1. In all animals, 20-µm
sections, each 100 µm apart, were analyzed; thus, the fraction of
sections sampled was 20/100 = 0.20. The number of neurons in
the analyzed region was estimated by multiplying the number of
neurons counted within the sample regions by the reciprocals of
the area sampling fraction and the fraction of section sampled.
Immunofluorescence
Animals were perfused and sections were prepared as described
above. Incubations and washes for all the antibodies were in
PBS, pH 7.4. All work was done at room temperature. For
double-labeling of Iba-1 with IκB kinase β (IKKβ) or arginase,
sections were blocked with PBS containing 1% goat serum
(Vector, for Iba-1) and rabbit serum (Invitrogen, for IKKβ or
arginase) for 1 h. The slides were washed three times in PBS
and then incubated overnight at 4◦C with either rabbit-derived
anti-Iba-1 (1:300; Wako), goat-derived anti-IKKβ (1:300; Santa
Cruz Biotechnology) and goat-derived anti-arginase (1:50; Santa
Cruz Biotechnology), diluted in PBS containing 1% goat/rabbit
serum and 0.25% Triton X-100. Sections were incubated with
goat anti-rabbit secondary antibody conjugated to Alexa Fluor R©
594 (1:200, for Iba-1; Invitrogen) and rabbit anti-goat secondary
antibody conjugated to fluorescein (1:200, for IKKβ and arginase;
Vector) for 1 h at 22 ± 1◦C in the dark and its addition was
preceded by three 10-min rinses in PBS. As a control, another
set of experiments was performed where the sections were only
incubated with the Iba-1 antibody and then visualized with both
filters. No signal was detected when Iba-1 alone with fluorescein
filter was used (photomicrograph not shown). The same was
true with IKKβ or arginase when Alexa Fluor R© 594 filter was
used. Fluorescence images were acquired using a confocal laser
scanning microscope (Zeiss LSM 7 DUO) and processed using
the associated software package (ZEN 2010).
Real-Time RT-PCR
BV2 cells were seeded at a concentration of 1 × 105 cells/well in
12-well plates (Sarstedt AG & Co., Germany) and then treated
with LPS (1 µg/ml) or IL-4 (20 ng/ml), with and without
metformin (1 mM). Treatments were conducted for 12 h. At
the end of the treatment, cells were collected in TRIsureTM
(Bioline, USA Inc.) and RNA was extracted from cells following
the manufacturer’s protocol. cDNA was synthesized using 1 µg of
extracted RNA using Revert Aid First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific) in 20 µL reaction volume as described
by the manufacturer.
Animals used for RT-PCR followed the procedure described
above but were sacrificed by decapitation 6 h after LPS/saline
injection in the SN, thus they only received a single dose of
metformin/water orally 1 h before the LPS/saline injection.
SN was dissected from each rat, snap frozen in liquid nitrogen
and stored at −80◦C. Total RNA was extracted from the rat SN
of different treatments using RNeasy R© kit (Qiagen). cDNA was
synthesized from 1 µg of total RNA using Revert Aid First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific) in 20 µL reaction
volume as described by the manufacturer.
Real-time PCR was performed using 5 µL SensiFASTTM
SYBR NO-ROX KIT (Bioline, United States), 0.4 µL of each
primer, and 4.2 µL cDNA to get to a final reaction volume
of 10 µL for 384-well plate. Controls were carried out without
cDNA. Amplification was run in a Lightcycler R© 480 Instrument
II (Roche) thermal cycler at 95◦C for 2 min followed by 40 cycles
consisting of a denaturation phase for 5 s at 95◦C, followed
by a second phase of hybridization at 65◦C for 10 s, and a
final phase of elongation at 72◦C for 20 s. The process was
terminated by a final step of 7 min at 72◦C. Analysis confirmed
a single PCR product. β-actin served as reference gene and was
used for samples normalization. The cycle at which each sample
crossed a fluorescence threshold (Ct value) was determined,
and the triplicate values for each cDNA were averaged. The
primer sequences for IL-1β, TNF-α, iNOS, arginase, IL-10, IL-6,
CX3CR1, CD200, MCP-1, the heme-binding membrane-bound
phagocytic (NAPDH) subunits (p22phox and gp91phox) and
β-actin are shown in Tables 1, 2.
Western Blot
In order to obtain proteins from BV2 cell line, cells were
seeded in 6-well plates (Sarstedt AG & Co., Germany) at a
seeding concentration of 200 × 103 cell/well and left for 24 h
at 37◦C to reach the required confluency. Then, cells were
treated with LPS (1 µg/ml) and/or metformin (1 mM) for
3 h, followed by ATP (1 mM) for 1 h. At the end of the
treatment which lasted for 4 h cells were collected in 50 µl RIPA
buffer (Sigma-Aldrich, St. Louis, MO, United States) with the
aid of a scraper after being washed three times with ice-cold
PBS. Cells lysate was sonicated (10% amplitude, 10 s, on ice)
using a probe sonicater (Hielscher Ultrasound Technology).
All steps were carried out on ice. Protein concentrations were
determined using PierceTM BCA protein assay kit (Thermo
Fischer Scientific).
Animals used for Western blot followed the procedure
described above and were sacrificed by decapitation 7 days after
LPS/saline injection in the SN. Proteins were extracted from the
SN of rat brains through the addition of 350 µl RIPA buffer
along with 3.5 µl protease inhibitor followed by sonication (10%
amplitude, 10 s, on ice). Afterwards, samples were heated in the
thermoblock for 5 min at 37◦C, left 20 min on ice and centrifuged
(4◦C, 13,000× g, 15 min). The clear supernatant which contained
the proteins was collected and quantified with PierceTM BCA
protein assay kit (Thermo Fischer Scientific).
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TABLE 1 | RT-PCR primers in vitro.
mRNA Primers
IL-1β F: 5′-TTGACGGACCCCAAAAGATG-3′
R: 5′-AGAAGGTGCTCATGTCCTCA-3′
TNF-α F: 5′-AGCCCACGTCGTAGCAAACCACCAA-3′
R: 5′-AACACCCATTCCCTTCACAGAGCAAT-3′
iNOS F: 5′-CTTTGCCACGGACGAGAC-3′
R: 5′-TCATTGTACTCTGAGGGCTGAC-3′
Arginase F: 5′- TCA CCT GAG CTT TGA TGT CG -3′
R: 5′- CTG AAA GGA GCC CTG TCT TG -3′
IL-10 F: 5′- CCAAGCCTTATCGGAAATGA -3′
R: 5′- TTTTCACAGGGGAGAAATCG -3′
β-actin F: 5′-CCA CAC CCG CCA CCA GTT CG-3′
R: 5′-CCC ATT CCC ACC ATC ACA CC-3′
p22phox F: 5′-GAATTCCGATGGGCAGATCGA-3′
R: 5′-GGAQTCCCGTCACACGACCTCA-3′
gp91phox F:5′-GCACAGCCAGTAGAAGTAGATCTTT-3′
R: 5′-GCTGGGATTGGAGTCACG-3′
TABLE 2 | RT-PCR primers in vivo.
mRNA Primers
TNF-α F: 5′-TACTGAACTTCGGGGTGATTGGTCC-3′
R: 5′-CAGCCTTGTCCCTTGAAGAGAACC-3′
IL-6 F: 5′-AAAATCTGCTCTGGTCTTCTGG-3′
R: 5′-GGTTTGCCGAGTAGACCTCA-3′
IL-1β F: 5′-CAGGATGAGGACATGAGCACC-3′
R: 5′-CTCTGCAGACTCAAACTCCAC-3′
iNOS F: 5′-CCTCCTCCACCCTACCAAGT-3′
R: 5′-CACCCAAAGTGCTTCAGTCA-3′
CD200 F: 5′-TGTTCCGCTGATTGTTGGC-3′
R: 5′- ATGGACACATTACGGTTGCC-3′
CX3CR1 F: 5′-GGC CTT GTC TGA TCT GCT GTT TG-3′
R: 5′- AAT GCT GAT GAC GGT GAT GAA GAA-3′
MCP-1 F: 5′-AGCATCCACGTGCTGTCTC-3′
R: 5′-GATCATCTTGCCAGTGAATGAG-3′
β-actin F: 5′-TGTGATGGTGGGAATGGGTCAG-3′
R: 5′-TTTGATGTCACGCACGATTTCC-3′
Proteins (40 µg) were separated on 10% SDS-PAGE gel,
subjected to electrophoresis at 150 V, and then transferred using
Trans-Blot R© TurboTM Transfer System (Bio-Rad Laboratories,
Hercules, CA, United States) onto 0.45 µm nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA, United States)
for 7 min.
After blocking with 5% skimmed milk diluted in TBST
(0.05% tween 20 in TBS) for 1 h, membranes were incubated
with a primary antibody against phosphorylated and
non-phosphorylated forms of the MAPKs family proteins
p38 and JNK (Santa Cruz Biotechnology) for in vivo experiment,
and against IL-1β (R&D Systems, Minneapolis, United States)
for in vitro experiment. Antibodies of non-phosphorylated
forms of MAPKs and the housekeeping GAPDH were used at
a dilution of 1:1000 in 5% skimmed milk dissolved in TBST,
while the antibodies of the phosphorylated forms of MAPKs
and IL-1β were used at a dilution of 1:500 in 5% skimmed
milk dissolved in TBST. Membranes were incubated with these
antibodies for 24 h at 4◦C. Membranes were washed 4 times
(10 min each) with TBST, then incubated for 1 h with the
secondary antibody (1:5000) in 5% skimmed milk dissolved in
TBST against the specific primary antibody at room temperature.
Another 4 washes with TBST (10 min each) were done before
visualizing the bands with ClarityTM and Clarity MaxTM western
ECL Blotting Substrates (Bio-Rad Laboratories, Hercules, CA,
United States) using Amersham Imager 600 Imager (General
Electric, United States). These images were later analyzed using
the ImageJ software.
Production of Reactive Oxygen Species
To determine the level of oxidative stress produced in viable
BV2 cell cultures 35 × 103 cells/well were seeded in Ibidi R© plates
(Invitrogen, Carlsbad, CA, United States) and incubated for 24 h
at 37◦C. Then cells were treated with metformin (1 mM) and/or
LPS (1 µg/ml) for 24 h. At the end of the treatment a membrane
permeable reagent was added (CellROX R© Deep Red Reagent)
at each well. This reagent is a fluorogenic probe that exhibits
fluorescence signal in the presence of ROS in the cell cytoplasm.
The test was performed following the manufacturer
instructions. The reactive was added to the treated cells at
a final concentration of 5 mM, and incubated at 37◦C for 30 min.
Subsequently, the media was removed and cells were washed
with PBS three times. Confocal microscope (Zeiss LSM 7 DUO)
was employed to acquire images of the treated cells. Images
of five fields per condition were captured. These images were
later analyzed using the ImageJ software. In each image, the
fluorescence per cell corresponding to ROS production was
calculated using the following formula:
ROS = (IT − (AT∗IB)/AB))/N, where IT is total intensity of the
image, AT is total area of the image, IB is background intensity,
AB is background area and N is number of cells.
Enzyme-Linked Immunosorbent Assay
BV2 cells were seeded in 24-well plates (Sarstedt AG & Co.,
Germany) at a concentration of 75 × 103 cells per well for 24 h.
Then, cells were treated with metformin (1 mM) and/or LPS
(1 µg/mL) and incubated at 37◦C for 3 h. After this time ATP
(1mM) was added at each well for 1 h. At the end of the treatment,
the supernatant was collected, centrifuged at 400× g 5 min at 4◦C
to remove cell debris and stored at −80◦C for subsequent use.
100 µl of the supernatant was used for the measurement of IL-1β
production by ELISA following the manufacturer’s instructions
(Invitrogen, Mouse IL1β ELISA Ready-SET-GO! Thermo Fisher
Scientific). All standards and samples were run in duplicates.
The supernatant was spun before removing cell debris. Samples
were diluted in a proportion of 1:1 in ELISA/ELISASPOT Diluent
(1×), except samples from cells treated with LPS alone which
were diluted in a proportion of 1:2.
Statistical Analysis
Results are expressed as mean ± SD. Means were compared
by One-Way ANOVA followed by the LSD test for post hoc
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multiple range comparisons. An alpha level of 0.05 was used. The
Statgraphics Plus 3.0 statistical package was used for the analyses.
RESULTS
Metformin Treatment Reduced Microglial
Activation in vitro
BV2 cells were treated with either LPS to induce a
pro-inflammatory phenotype or IL-4 to induce an
anti-inflammatory phenotype. After treatment with LPS, a
strong induction of the three pro-inflammatory mediators
studied was found, ranging from 348% for TNF-α to 1438% for
IL-1β (with respect to control levels; p < 0.001; Figures 2A–C).
Metformin treatment largely prevented the LPS-induced
mRNA expression levels of IL-1β (56 ± 11.5% vs. LPS group;
p < 0.001; Figure 2A). In contrast, metformin failed to alter the
LPS-induced mRNA levels of nitric oxide synthase (iNOS) and
TNF-α (Figures 2B,C). When BV2 cells were treated with IL-4, a
strong induction of arginase (20000-fold compared to the control
group, p < 0.001; Figure 2D) was found. This IL-4-induced
upregulation was largely prevented by metformin treatment
(63.3 ± 12.5% vs. IL-4 group; p < 0.001; Figure 2D). IL-10
mRNA levels were unaffected in response to IL-4 (Figure 2). No
effect was found in the amounts of IL-10 mRNA when metformin
was added to IL-4-treated cells (Figure 2E).
Metformin Treatment Decreased the
Production of Reactive Oxygen Species
Taking into account that the main source of ROS in microglial
cells is the NADPH oxidase, we next sought to measure the level
of oxidative stress after the treatments with LPS and metformin.
We took advantage of a fluorogenic probe that exhibits
fluorescence signal in the presence of ROS. As expected, LPS
induced a two-fold increase of ROS production (197.1 ± 31.6%
with respect to the control, p< 0.001; Figures 3A–C,E), whereas
metformin decreased it around 30% (138.8 ± 9.7% with respect
to the control, p< 0.001; Figures 3D,E).
Metformin Treatment Prevented the
Induction of NADPH Oxidase by LPS
In microglial cells, ROS are mainly derived from NADPH oxidase
(Block, 2008; Gao et al., 2012). This enzyme complex consists on
several subunits, including cytosolic subunits (p40phox, p47phox,
and p67phox), the membrane bound cytochrome b558 (p22phox),
the heme binding enzymatic subunit (gp91phox) and the Rac
G-protein (Dohi et al., 2010). After a pathogenic stimulus, the
different subunits of the NADPH oxidase associates leading to
its activation (Block, 2008; Gao et al., 2012). Therefore, the
expression levels of the p22phox and gp91phox subunits of the
NADPH oxidase enzyme were measured by RT-PCR to study the
effect of metformin on the oxidative stress induced by LPS in BV2
cells. mRNA levels of p22phox and gp91phox subunits significantly
increased after LPS treatment (251.1± 74.2% and 524.8± 222.7%
control levels, respectively; Figures 3F,G; p < 0.05). Metformin
treatment prevented the LPS-induced mRNA levels of both
p22phox and gp91phox subunits, which remained not different to
control values (173.2 ± 21.7% and 308.7 ± 136.9%, p < 0.05,
Figures 3F,G).
Metformin Treatment Decreased the
Number of Activated Microglial Cells
in vivo
Once we demonstrated that metformin treatment reduces
microglial activation in response to LPS in vitro, we next studied
whether this was also the case in the SN after LPS injection in vivo
at morphological and molecular levels. Immunohistochemistry
was performed with a marker of reactive microglia (OX-6)
to evaluate the effect of metformin on the LPS-associated
neuroinflammation. Both control and metformin groups showed
a similar mild OX-6 immunoreactivity around the injection
tract (Figures 4A,B,E). In contrast, the LPS-treated group
showed a clear microglial activation, nearly 10 times higher
than the control group (1141.9 ± 207.8 cells/mm2, p < 0.01;
Figures 4C,E). Metformin hindered LPS-induced microglia
activation by almost half (584.2 ± 230.1 cells/mm2, p < 0.01;
Figures 4D,E). Therefore, metformin significantly decreased the
inflammation caused by LPS.
Metformin Treatment Failed to Protect
Against LPS-Induced Damage to
Astrocytes
In previous works, we have shown that the intranigral injection
of LPS induces a significant loss of GFAP-reactive astrocytes
extending from the injection site (Castaño et al., 1998; Castan´o
et al., 2002; Herrera et al., 2000). Consequently, we next analyzed
the astroglial population in our experimental conditions. As
expected, in absence of LPS, a slight astrogliosis around the
injection site was found in saline-injected animals from both
control and metformin-treated animals without loss of GFAP
immunostaining (Figures 4F,G,J). In confirmation of previous
reports, a significant loss of GFAP-reactive astrocytes extending
from the injection site was evident in LPS-injected animals
(2.30 ± 1.48 mm2; p < 0.05 vs. controls). The area exhibiting
GFAP loss was surrounded by highly reactive astrocytes
(Figures 4H,J). Metformin treatment failed to prevent the loss
of astrocytes in response to LPS injection (2.78 ± 1.48 mm2;
Figures 4I,J).
Metformin Treatment Attenuated the
Expression Levels of Several
Inflammatory Mediators After LPS
Injection in vivo
Activated microglia expresses pro-inflammatory cytokines and
several pro-inflammatory mediators. Analysis by real-time PCR
showed that the mRNAs for the pro-inflammatory cytokines
TNF-α, IL-1β, and IL-6 were induced in the SN 6 h after LPS
injection (496.3 ± 53.0%, 243,3 ± 96%, and 172.5 ± 21.9%
control levels, respectively; p < 0.01; Figures 5A–C). Moreover,
LPS treatment induced the expression of MCP-1 (369.0 ± 87.0%
with respect to the control; p< 0.001; Figure 5E).
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FIGURE 2 | Expression levels of the mRNAs of IL-1β (A), iNOS (B), TNF-α (C), arginase (D), and IL-10 (E) in BV2 cells. Total RNA was extracted from cells after 12 h
of treatment (LPS for IL-1β, iNOS and TNF-α; IL-4 for arginase and IL-10). Results are mean ± SD of three independent experiments, normalized to β-actin and
expressed as percentage relative to the LPS or IL-4 group. Statistical significance (one-way ANOVA followed by the LSD post hoc test for multiple comparisons): a,
compared with the control group; b, compared with the metformin group; c, compared with the LPS (or IL-4; D,E) groups; p < 0.001. (C, control cells without
treatment; Metf, cells treated with metformin; LPS, cells treated with LPS; IL4, cells treated with IL-4; LPSMetf, cells treated with LPS and metformin; IL4Metf, cells
treated with IL-4 and metformin).
CD200 and CX3CR1 have shown to have inhibitory actions
on brain microglia. Hence, we decided to study these molecules
in our experimental conditions to seek further explanations of
how metformin induces an attenuated effect after LPS treatment.
Our PCR analysis showed that the expression of CD200 and
CX3CR1 mRNAs is decreased with respect to the control group
(40.0± 2.5% and 71.1± 12.7%, respectively; p< 0.001 for CD200
and p< 0.05 for CX3CR1; Figures 5F,G).
Metformin significantly partially prevented the LPS-induced
increases in the mRNA levels of inflammatory markers studied
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FIGURE 3 | Effect of LPS and metformin on ROS production and expression levels of NADPH oxidase subunits in BV2 cells. ROS were measured 24 h after the
different treatments assayed: (A) control; (B) metformin; (C) LPS; (D) LPS plus metformin. (E) Quantification of ROS production. Results are mean ± SD of 3
independent experiments, expressed as percentage of control. Scale bar, 50 µm. Expression levels of p22phox (F) and gp91phox (G) mRNAs were measured by
RT-PCR in BV2 cells from the different treatments assayed (C, control cells without treatment; Metf, cells treated with metformin; LPS, cells treated with LPS;
LPSMetf, cells treated with LPS and metformin). Results are mean ± SD of three independent experiments for the Metf, LPS, and LPSMetf groups, and 4 (gp91phox)
and 5 (p22phox ) independent experiments for the C group. Results are normalized to β-actin and expressed as percentage relative to the control group. Statistical
significance (one-way ANOVA followed by the LSD post hoc test for multiple comparisons): a, compared with the control group; b, compared with the Metf group; c,
compared with the LPS group. p < 0.001 for (E) and p < 0.05 for (F,G).
including TNF-α (322.9 ± 67.6% controls); IL-1β (38.1 ± 13.5%
controls) and IL-6 (122.5 ± 18.8% controls) (Figures 5A–C;
p < 0.01). On the contrary, metformin treatment further
increased the LPS-induced MCP-1 levels (619.7± 59.2% controls,
p < 0.001) and, interestingly, prevented the LPS-induced
decreased mRNA levels of CD200 (68.0 ± 10.5%, p < 0.001) and
CX3CR1 (110.2± 12.1% controls, p< 0.05) (Figures 5E–G).
Metformin Attenuated the LPS-Induced
Microglial Pro-inflammatory Phenotype
To study the effect of metformin on the phenotype of microglial
cells challenged by LPS, a double immunohistochemistry using
a pan-microglia marker (Iba-1) with either a pro-inflammatory
(IKKβ) or an anti-inflammatory (arginase) marker was
performed (Figure 5H and Supplementary Figures S1, S2).
After treatment with LPS, most microglial cells co-localized
with IKKβ (Figure 5H; p < 0.001) but not with arginase (scarce
co-localization), thus supporting the appearance of a strong
microglial pro-inflammatory phenotype. When animals were
treated orally with metformin, most microglial cells expressed
IKKβ, whereas no co-localization appeared with arginase.
Therefore, LPS also induces a pro-inflammatory phenotype even
in metformin-treated animals.
Metformin Treatment Decreased the
Activation of the Inflammasome
In microglial cells the nucleotide-binding oligomerization
domain-like receptor protein containing a pyrin domain 3
(NLRP3) inflammasome activation follows a two-signal model;
a first signal (priming response) is, for instance, provided
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FIGURE 4 | Effect of metformin and LPS on microglia and astroglia, evaluated
by immunohistochemistry with the OX-6 (microglia; A–D) and the anti-GFAP
(astroglia, F–I) antibodies. (A,F) Animals injected with saline solution in the SN
plus oral administration of water; (B,G) animals injected with saline solution in
the SN plus oral administration of metformin; (C,H) animals injected with LPS
in the SN plus oral administration of water; (D,I), animals injected with LPS in
the SN plus oral administration of metformin. The activation of microglia
induced by LPS (C) was partially prevented by metformin (D). GFAP
immunohistochemistry showed an important loss of astroglia induced by LPS
(H) that was not prevented by metformin (I). The dashed line in (H,I) marks the
left boundary of the area lacking GFAP staining. Metformin alone had no effect
on either microglia (B) or astroglia (G). (E) Quantification of the density of
OX-6 positive cells. Results are mean ± SD of four independent experiments,
expressed as number of cells per mm2. (J) Quantification of the areas lacking
GFAP immunostaining. Results are mean ± SD of four independent
experiments, expressed as mm2. Statistical significance (one-way ANOVA
followed by the LSD post hoc test for multiple comparisons): a, compared
with the control group; b, compared with the SalMetf group; c, compared with
the LPS group; p < 0.01 for (E) and p < 0.05 for (J). Scale bar, 50 µm.
by Toll-like receptor (TLR) activation leading to NLRP3
and pro-IL-1β expression; a second signal (activation) is
triggered, among others, by ATP or nigericin leading to
inflammasome assembly and caspase-1 activation (He et al.,
2016). Consequently, LPS followed by ATP treatment is a
well-established strategy to activate the NLRP3 inflammasome
(Martinon et al., 2002; Li et al., 2018). In our experimental
conditions, we used LPS as first signal and ATP as the second
one. We also have included another set of experiments only
with LPS as a first signal. When activated, NLRP3 inflammasome
induces the maturation of pro IL-1β into IL-1β through a
caspase 1 dependent mechanism, leading to the release of this
cytokine to the extracellular medium. We wanted to know
if metformin treatment was able to decrease inflammasome
activation after LPS/ATP treatment in BV2 cells. ELISA and
Western blot analysis confirmed that LPS/ATP treatment
increased the expression of both extracellular and intracellular
IL-1β, whereas metformin significantly prevented this effect
(around 50% vs. LPS/ATP group; p < 0.001; Figures 6A,B
and Supplementary Figures S3, S4). Similar results were found
when BV2 were challenged with LPS alone (in absence of ATP
treatment) (Supplementary Figures S3, S4), thus supporting that
TLR4 stimulation alone may drive inflammasome priming and
activation in BV2 cells without the need for a secondary signal.
This distinctive one-step pathway of inflammasome activation is
typically seen in monocytes and have been recently seen in recent
studies using BV2 cells (Carta et al., 2011; Huang M.Y. et al., 2018;
Yang et al., 2018).
Metformin Effects on Microglial
Activation Are Mediated by MAPK
As a further step, activation of MAPKs was determined by
Western blot analysis using specific antibodies against the
phosphorylated and non-phosphorylated forms of JNK and p38.
As expected, LPS treatment increased the ratio P-JNK/JNK
(153.7 ± 60.5%; p < 0.05 compared with control animals;
Figure 6C and Supplementary Figures S5, S6), whereas
metformin treatment abolished this effect (89.0 ± 33.7% of
control values; p < 0.05 compared with the LPS group). LPS
increased the ratio P-p38/p38 (141.52 ± 53.8%; p < 0.05
compared with control animals), whereas metformin treatment
reduced it (57.9 ± 29.2% of control values; p < 0.05 compared
with the LPS group; Figure 6D and Supplementary Figure S5).
Effect of Metformin and LPS on the
Dopaminergic System
Finally, we have evaluated the integrity of the nigro-striatal
dopaminergic neurons in terms of immunoreactivity of TH,
the rate-limiting enzyme in the synthesis of dopamine. Oral
administration of metformin (Figures 7B,E) had no effect on
the number of dopaminergic neurons with respect to the control
group (2882 ± 685 and 2294 ± 530 for control and metformin,
respectively; Figures 7A,B,E). Intranigral administration of LPS
reduced the number of neurons to 66.1% of control values
(Figures 7C,E; p < 0.01). Interestingly, metformin not only
failed to protect against the LPS-induced death of dopaminergic
neurons, but exacerbated the damage (29.6% of control value;
Figures 7D,E).
DISCUSSION
In this study, we have evaluated the effect of metformin
on microglia polarization, inflammasome activation, free
radical production and main immune checkpoints, including
CX3CL1/CX3CR1R and CD200/CD200R in response to LPS,
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FIGURE 5 | Effect of metformin and LPS on the expression of TNF-α (A), IL-1β (B), IL-6 (C), iNOS (D), MCP-1 (E), CD200 (F), and CX3CR1 (G) mRNAs in the SN of
rats from the different treatments assayed, measured by RT-PCR. Sal, animals injected with saline solution in the SN plus oral administration of water; SalMetf,
animals injected with saline solution in the SN plus oral administration of metformin; LPS, animals injected with LPS in the SN plus oral administration of water;
LPSMetf, animals injected with LPS in the SN plus oral administration of metformin. Results are mean ± SD of 4 independent experiments, normalized to β-actin and
expressed as percentage relative to the control (Sal) group. (H) Quantification of the effect of metformin and LPS on Iba-1, IKKβ and arginase immunostaining in the
SN. Arginase is poorly induced in Iba-1-labeled microglial cells after the treatments assayed. The expression of IKKβ is induced by LPS in Iba-1 positive cells, an
effect decreased by metformin. Results are mean ± SD of three independent experiments expressed as cells per mm2. Statistical significance (one-way ANOVA
followed by the LSD post hoc test for multiple comparisons): a, compared with the Sal group; b, compared with the SalMetf group; c, compared with the LPS group;
p < 0.001.
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FIGURE 6 | Effect of metformin and LPS on inflammasome activation in BV2 cells and expression of JNK, P-JNK, p38, and P-p38 proteins in the SN.
(A) Extracellular IL-1β measured by ELISA. (B) Intracellular IL-1β measured by Western blot. Results are mean ± SD of three independent experiments for all groups,
expressed as ng/ml (A), and three independent experiments for all groups, expressed as percentage of the L/A group (B); intracellular amounts are normalized to
GAPDH expression. Statistical significance (one-way ANOVA followed by the LSD post hoc test for multiple comparisons): a, compared with the control group; b,
compared with the L/A group; c, compared with the L/M/A group; p < 0.001. (C) Control group; L/A, cells treated with LPS and ATP; L/M/A, cells treated with a
combination of LPS, metformin and ATP; M/A, cells treated with a combination of metformin and ATP; ND, not detected. Proteins from the SN of rats under the
different treatments assayed were separated by electrophoresis and transferred to nitrocellulose membranes, and stained using anti-JNK, anti-P-JNK, anti-p38 and
anti-P-p38 antibodies. Total optical density of each band was calculated. Results are mean ± SD of seven independent experiments for groups Sal, LPS and
LPSMetf and eight independent experiments for group SalMetf (C), and three independent experiments for groups Sal and LPS and four independent experiments
for groups SalMetf and LPSMetf (D), expressed as P-JNK/JNK (C) and P-p38/p38 (D) intensity ratios (normalized to GAPDH expression) relative to the control (Sal)
group. Statistical significance (one-way ANOVA followed by the LSD post hoc test for multiple comparisons): a, compared with the control (Sal) group; b, compared
with the SalMetf group; c, compared with the LPS group; p < 0.01.
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FIGURE 7 | Effect of metformin and LPS on dopaminergic neurons. TH
immunoreactivity was not affected by the injection of saline solution in the SN
of rats (A) and the administration of metformin (B), but decreased after the
injection of 2 µg of LPS (C). Loss of TH immunoreactivity induced by LPS
increased in the animals treated orally with metformin (D). Scale bar: 500 µm.
(E) Quantification of the number of TH-positive cells. Results are mean ± SD
of four independent experiments, expressed as TH-positive cells within the
bounded area of the SN. Statistical significance (one-way ANOVA followed by
the LSD post hoc test for multiple comparisons): a, compared with the control
(Sal) group; b, compared with the SalMetf group; c, compared with the LPS
group; p < 0.01.
in vivo and in vitro. Our study demonstrates that metformin
exhibits potent MAPK-dependent anti-inflammatory effects on
microglia in response to TLR activation. However, metformin
treatment failed to counteract the death of dopaminergic neurons
induced by a single intranigral injection of LPS.
It is becoming evident that microglia may display a
varied range of reaction states including pro-inflammatory,
anti-inflammatory and the recent disease-associated phenotype
(reviews, Keren-Shaul et al., 2017; Krasemann et al., 2017). As
a first step, we analyzed the effect of metformin on two well
defined methods of microglia polarization based on treatment
of BV2 cells with either LPS (pro-inflammatory stimulus) or
IL-4 (anti-inflammatory stimulus). Analysis of specific microglia
markers typically associated to these phenotypes (i.e., IL-1β
or arginase) demonstrated an overall immunosuppressive role
of metformin in driving the switch of homeostatic microglia
to both LPS-induced pro-inflammatory and IL-4-induced
anti-inflammatory phenotypes. Our results not only confirm the
anti-inflammatory properties of metformin (Isoda et al., 2006;
Łabuzek et al., 2010; Gu et al., 2014) but also reveals an overall
immunosuppressive role on microglial cells.
We next studied the effect of metformin on different
pro-inflammatory microglia-related pathways associated to
neurodegeneration, including the NADPH oxidase system
(Belarbi et al., 2017) and the NLRP3 inflammasome (Heneka
et al., 2018). NADPH activation generates superoxide, which is
released and then either transformed into H2O2 by extracellular
superoxide dismutase or reacts with NO to produce peroxynitrite
(Hickman et al., 2018). We followed a double in vitro approach
in BV2 cells challenged with LPS: (i) measurement of ROS
and (ii) measurement of levels of the p22phox and gp91phox
subunits of the NADPH oxidase. In keeping with the overall
immunosuppressant action of metformin, it highly prevented
both, LPS-induced formation of ROS and up-regulation of
p22phox and gp91phox subunits of the NADPH oxidase complex.
Inflammasomes are molecular platforms mediating
inflammatory responses through the maturation and
release of IL-1β through a caspase-1-dependent mechanism
(Zhou et al., 2010). NLRP3 is one of the most intensively
investigated inflammasomes, controlling disease progression and
inflammatory responses (Yang et al., 2014). It has been shown
that metformin is able to decrease the activation of NLRP3 in
various tissues (Lee et al., 2013; Bullón et al., 2016; Li et al.,
2016). Different studies have reported rather contradictory
effects of metformin on NLRP3 inflammasome activation in
macrophages, including inhibition (Kelly et al., 2015) and
activation (Zha et al., 2016). To our knowledge, the effect of
metformin on NLRP3 activation in microglial cells has never
been studied. We provide evidence that metformin inhibits the
NLRP3 inflammasome priming and activation in microglia.
Overall, our data demonstrate a robust anti-inflammatory effect
of metformin on LPS-stimulated microglial cells.
Given the strong effect of metformin on immune-related
neurodegeneration pathways, we analyzed the potential
anti-inflammatory effect of metformin in an in vivo model of
PD associated to neuroinflammation. To date only a few studies
have analyzed the effect of metformin on in vivo PD animal
models, which were restricted to that based on MPTP injection
(Patil et al., 2014; Bayliss et al., 2016; Ismaiel et al., 2016; Lu
et al., 2016). However, MPTP-based PD models relies primarily
on complex I inhibition but not on neuroinflammation itself
(Bové and Perier, 2012; Machado et al., 2016). Hence, we have
studied for the first time the effect of metformin in response to
intranigral injection of LPS within the SN, a well-established
and extensively used neuroinflammation-based model of PD
(Herrera et al., 2005; Dutta et al., 2008). We analyzed the
degree of microglia activation (OX-6 immunoreactivity) and
polarization (pro-inflammatory/anti-inflammatory markers) and
immunological checkpoints (CX3CR1 and CD200 expression).
Our in vivo model using intranigral LPS revealed that metformin
treatment decreased both the number of activated microglial
cells and the acquisition of pro-inflammatory markers. Among
the last ones, a remarkable effect of metformin in preventing
LPS-induced IL-1β mRNA levels was found, thus further
supporting our in vitro study showing that metformin highly
inhibits NLRP3 inflammasome priming in microglia.
Under brain pathological conditions, microglial checkpoints
pathways sense the environment to prevent overreaction
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to external stimuli. However, such checkpoint mechanisms
may also limit the ability of microglia to protect the CNS
(Deczkowska et al., 2018; Hickman et al., 2018). These include
(a) CX3CR1–fractalkine sensing, which is highly relevant in
homeostatic microglia (Keren-Shaul et al., 2017; Krasemann
et al., 2017). Still, activation of CX3CR1 has been related to
a decrease in the neurotoxic actions of microglia (Cardona
et al., 2006); (b) CD200/CD200R, which attenuates microglia
activation especially under inflammatory conditions (Barclay
et al., 2002). CD200 is an extrinsic factor produced by neurons,
astrocytes and oligodendrocytes; in the CNS, its receptor
CD200R appears exclusively in microglia and macrophages
(Hoek et al., 2000; Barclay et al., 2002; Biber et al., 2007). As
expected, LPS injection downregulated the expression of both
CD200 and CX3CR1 mRNAs in the ventral mesencephalon.
Strikingly, metformin treatment full prevented the LPS-induced
downregulation of CD200 and CX3CR1. To our knowledge,
this is the first report pointing up metformin as a molecule
responsible for inactivating microglia through checkpoints
pathways.
Mitogen-activated protein kinases are a family of
serine/threonine protein kinases that play important roles
in signal transduction from a diverse array of extracellular
stimuli, including LPS (Qin et al., 2007). This family of
proteins is involved in the survival, proliferation, differentiation
and apoptosis of nervous cells, therefore playing a role in
neuroprotection/neurodegeneration (Kim and Choi, 2010).
In previous works, we have demonstrated that LPS is able
to increase the phosphorylation levels of JNK and p38 in
different brain structures, and that these levels increase with
the co-existence of other pro-inflammatory stimuli, such as
chronic stress (Espinosa-Oliva et al., 2011). We thus studied
the effect of metformin on the expression of key MAPKs
after LPS treatment. Metformin treatment prevented the
LPS-induced phosphorylation of JNK and p38 in LPS-injected
rats. These results support the additional involvement of
MAPKs signaling pathway in the immunosuppressive role
of metformin in brain inflammation. Taken together, we
provide evidence that metformin inhibits microglia reactivity
through different mechanisms including MAPK signaling
and checkpoints pathways thus reducing typical features of
pro-inflammatory microglia including NADPH-dependent
production of free radicals and NLRP3 inflammasome priming
and activation.
Since the intranigral injection of LPS is a neuroinflammation-
based model of PD (Castaño et al., 1998; Herrera et al., 2000),
we analyzed the effect of metformin on the integrity of the
nigrostriatal dopaminergic system. Unexpectedly, metformin
treatment not only failed to protect the LPS-induced damage
to the nigral dopaminergic system but exacerbated it. Our data
support a metformin-associated inflammation-independent
deleterious effect on the integrity of the nigrostriatal
dopaminergic system. A distinguished feature of nigral
dopaminergic neurons is the extremely complex axonal
arborization that would greatly exceed those of other neuronal
phenotypes and hence the associated energy demand (Pissadaki
and Bolam, 2013; Hunn et al., 2015). Complex I deficiency has
been long associated with mitochondrial dysfunction and PD
risk (Schapira and Jenner, 2011). Interestingly, metformin is a
weak inhibitor of complex I of the mitochondrial respiratory
chain that may be critical under stressful conditions (El-Mir
et al., 2000; Owen et al., 2000). In keeping with this view, we
have demonstrated that metformin exacerbated dopaminergic
damage in response to MPTP, a well-known complex I inhibitor
(Ismaiel et al., 2016). The present study confirms and extends
the view that metformin may be harmful to the dopaminergic
system under different conditions including MPTP challenge
or robust LPS-induced brain inflammation. Metformin is the
first-choice treatment of diabetes mellitus II, a disease with
high prevalence nowadays that seems to be a risk factor for
some neurodegenerative diseases such as PD (Hu et al., 2007;
Simon et al., 2007; Driver et al., 2008; D’Amelio et al., 2009;
Miyake et al., 2010; Schernhammer et al., 2011; Xu et al., 2011).
Only a few studies have addressed the effect of metformin
on PD animal models with apparently conflicting effects,
including beneficial (Patil et al., 2014; Lu et al., 2016; Katila et al.,
2017) or detrimental (Chen et al., 2016; Ismaiel et al., 2016;
Kuan et al., 2017; Thangthaeng et al., 2017). Although these
apparent contradictory results may be due to differences in the
experimental design, our study urges the need to carefully assess
the use of metformin for the treatment of diabetes in patients
who may suffer from PD.
AUTHOR CONTRIBUTIONS
KT and IG-D carried out the cell cultures, PCR, and
WB. AI executed surgery, immunohistochemistry, and
immunofluorescence techniques. AB-S and TD contributed
with the cell culture. AE-O carried out the analysis and
interpretation of data, and contributed to writing the
manuscript. AM helped with the writing of the manuscript. AH
contributed to statistical analysis and helped with the writing.
JV contributed to experimental design and coordination, and
helped with the writing. RdP conceived the study, contributed
to experimental design and coordination, and helped with the
writing.
FUNDING
This work was supported by a grant from the Spanish
Ministerio de Economia y Competitividad SAF2015-64171-R
(MINECO/FEDER, EU). KT was supported by a studentship
provided by Erasmus Mundus -Phoenix Programme. IG-D was
supported by pre-doctoral fellowships from Spanish Ministerio
de Educación, Cultura y Deporte.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fncel.2018.
00440/full#supplementary-material
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 November 2018 | Volume 12 | Article 440
fncel-12-00440 November 19, 2018 Time: 14:41 # 14
Tayara et al. Metformin Beneficial and Harmful Effects
FIGURE S1 | Effect of metformin on Iba-1, IKKβ and arginase immunostaining in
the SN after saline solution (A–C,G–I) and SalMetf (D–F,J–L) treatments. Iba-1
immunofluorescence in (A,D), and IKKβ immunofluorescence in (B,E), show a
scarce induction of IKKβ in Iba-1-labeled microglial cells (merge, C,F). Arginase
(H,K) is not induced in Iba-1-labeled microglial cells (G,H,J,K; merge I,L) in the
animals treated with saline solution and SalMetf. Scale bar: 200 µm.
FIGURE S2 | Effect of metformin and LPS on Iba-1, IKKβ and arginase
immunostaining in the SN after LPS (A–C,G–I) and LPSMetf (D–F,J–L)
treatments. Iba-1 immunofluorescence in (A,D), and IKKβ immunofluorescence in
(B,E) show an induction of IKKβ in Iba-1-labeled microglial cells (merge C,F).
Arginase (H,K) is not induced in Iba-1-labeled microglial cells, except for a few
ones (G,H,J,K; merge I,L) in the animals treated with LPS and LPSMetf. Images in
the inserts in (C,F,I,L) are high-magnification photographs of the small white
boxes in their respective panels. Scale bars: (A–L), 200 µm; insert, 25 µm.
FIGURE S3 | Photographs showing raw bands of IL-1b and GAPDH for the
different treatments assayed (four independent experiments in each case).
Treatments to BV2 cells: 1, none (control); 2, LPS; 3, ATP; 4, metformin; 5,
LPS + metformin; 6, ATP + metformin; 7, LPS + ATP; 8, LPS + ATP + metformin.
FIGURE S4 | Photographs showing raw bands of IL-1b and GAPDH for the
different treatments assayed (three independent experiments in each case).
Treatments to BV2 cells: 1, none (control); 2, LPS; 3, LPS + metformin; 4, ATP; 5,
LPS + ATP; 6, LPS + ATP + metformin; 7, Metformin; 8, Metformin + ATP.
FIGURE S5 | Photographs showing raw bands of GAPDH, JNK, P-JNK, p38, and
P-p38 for the different treatments assayed (four independent experiments in each
case). Sal, animals injected with saline solution in the SN plus oral administration
of water; SalMetf, animals injected with saline solution in the SN plus oral
administration of metformin; LPS, animals injected with LPS in the SN plus oral
administration of water; LPSMetf, animals injected with LPS in the SN plus oral
administration of metformin.
FIGURE S6 | Photographs showing raw bands of JNK, P-JNK, and GAPDH for
the different treatments assayed (four independent experiments in each case).
Treatments: 1 and 5, Sal, animals injected with saline solution in the SN plus oral
administration of water; 2 and 6, SalMetf, animals injected with saline solution in
the SN plus oral administration of metformin; 3 and 7, LPS, animals injected with
LPS in the SN plus oral administration of water; 4 and 8, LPSMetf, animals
injected with LPS in the SN plus oral administration of metformin.
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